Lack of efficacy following off label use: case report

In a retrospective follow-up study conducted between January 2019 and December 2019, one patient (age and sex not stated) was described, who exhibited lack of efficacy with off-label curcumin while being treated for mild cognitive impairment. The patient with mild cognitive impairment, started receiving oral off-label curcumin [theracurmin] 180 mg/day. However, the patient progressed to Alzheimer’s Disease, indicating lack of efficacy with curcumin treatment.

Dost FS, et al. Theracurmin Supplementation May be a Therapeutic Option for Older Patients with Alzheimer’s Disease: A 6-Month Retrospective Follow-Up Study. Current Alzheimer Research 18: 1087-1092, No. 14, 2021. Available from: URL: http://doi.org/10.2174/1567205019666211221125255